A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Inclusion Criteria:

Participants must have been diagnosed with relapsing MS

Participants must have one of the following

at least 1 documented relapse within the previous year, or
at least 2 documented relapse within the previous 2 years, or
at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

Have had a diagnosis of primary progressive MS
Have a history of another clinically significant neurological disease
Had a relapse of MS within 30 days prior to randomization.